Drug Profile
Fluasterone - SteroTherapeutics
Alternative Names: ST 001; ST 002; ST-001 - SteroTherapeutics; ST-002 - SteroTherapeuticsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Fels Institute for Cancer Research and Molecular Biology
- Developer SteroTherapeutics
- Class Androstenols; Anorectics; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Hepatoprotectants; Phenanthrenes; Small molecules; Testosterone congeners
- Mechanism of Action Glucose-6-phosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 28 May 2022 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in USA
- 28 Mar 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA